ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results…
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go…
Surgical oncologist Dr. Edward Levine was not surprised by the encouraging results of the recent study measuring quality-of-life issues following aggressive treatment for…
Italian researchers have found early success using gold nanoparticles as a chemotherapy-delivery vehicle for mesothelioma. They are hopeful their discovery will lead…
Aggressive surgery for the treatment of malignant pleural mesothelioma is being underutilized, costing patients significant survival time, according to a recent study. Researchers…
Deaths attributed to asbestos exposure — within the United States and worldwide — have been significantly underestimated, according to the latest study by the…
Scientists with the United States Geology Survey (USGS) have created a hand-held spectrometer to determine if vermiculite insulation contains deadly amphibole asbestos. The…
Dr. Antonio Giordano believes his team has cleared the path to the next breakthrough in the treatment of malignant pleural mesothelioma. The advancement…
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
Reviewed & Fact-Checked
This page was reviewed by:
Fact-checked and verified content:
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Please read our editorial guidelines to learn more about our content creation and review process.
